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Anti-DNA autoantibodies initiate experimental lupus
nephritis by binding directly to the glomerular
basement membrane in mice
Meera R. Krishnan1,2, Congmiao Wang1,2,3 and Tony N. Marion1
1Department of Microbiology, Immunology, and Biochemistry, The University of Tennessee Health Science Center, Memphis,
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The strongest serological correlate for lupus nephritis is
antibody to double-stranded DNA, although the mechanism
by which anti-DNA antibodies initiate lupus nephritis is
unresolved. Most recent reports indicate that anti-DNA must
bind chromatin in the glomerular basement membrane or
mesangial matrix to form glomerular deposits. Here we
determined whether direct binding of anti-DNA antibody to
glomerular basement membrane is critical to initiate
glomerular binding of anti-DNA in experimental lupus
nephritis. Mice were co-injected with IgG monoclonal
antibodies or hybridomas with similar specificity for DNA and
chromatin but different IgG subclass and different relative
affinity for basement membrane. Only anti-DNA antibodies
that bound basement membrane bound to glomeruli,
activated complement, and induced proteinuria whether
injected alone or co-injected with a non-basement-
membrane–binding anti-DNA antibody. Basement
membrane–binding anti-DNA antibodies co-localized with
heparan sulfate proteoglycan in glomerular basement
membrane and mesangial matrix but not with chromatin.
Thus, direct binding of anti-DNA antibody to antigens in
the glomerular basement membrane or mesangial matrix
may be critical to initiate glomerular inflammation. This
may accelerate and exacerbate glomerular immune complex
formation in human and murine lupus nephritis.
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The contribution of anti-DNA antibody to glomerulone-
phritis in mouse1 and human2 systemic lupus erythematosus
is well established. Although anti-double-stranded DNA
(dsDNA) antibody is the best serological correlate for lupus
nephritis,3,4 the frequent lack of correlation between serum
anti-dsDNA and glomerulonephritis is a long recognized
conundrum in the clinical evaluation of individual systemic
lupus erythematosus patients.3,5,6 The lack of correlation
between anti-dsDNA and lupus nephritis within individual
patients may be a consequence of how anti-dsDNA antibodies
bind in the glomerulus and initiate glomerulonephritis,6 a
process not yet fully resolved.7 Mechanisms proposed to
explain glomerular deposition of anti-DNA antibody include
glomerular binding of soluble immune complexes of nucleo-
somes and immunoglobulin G (IgG) anti-DNA,2,8–10 in situ
formation of immune complexes when anti-DNA antibody
binds to chromatin that has bound to glomerular basement
membrane (GBM) or mesangial matrix (MM),11–17 and direct
binding of anti-DNA antibody that cross-reacts with GBM or
cell surface antigens.18–25 Recent morphological studies12–14,16
have identified chromatin and IgG within the glomerular
subendothelial and subepithelial electron-dense deposits
(EDS) in nephritic kidneys from lupus patients26 and lupus-
prone mice.27 The recent results were interpreted to indicate
that anti-DNA antibody could form glomerular deposits only
when bound to chromatin or nucleosomes.28–30
The present experiments were designed to test the
hypothesis that initial glomerular binding of anti-DNA
antibody in lupus nephritis is a function of direct, cross-
reactive binding to glomerular antigens, particularly in GBM
or MM, and independent of DNA, nucleosomes, or
chromatin. The experiments took advantage of a panel of
anti-DNA monoclonal antibodies (mAbs) with similar
relative affinities for DNA and chromatin, but different
relative affinities for basement membrane (BM) antigens in
GBM and MM. Only anti-DNA mAbs that also bound BM
antigens bound glomeruli in vivo and induced proteinuria.
Glomerular binding of the anti-DNA mAbs was independent
of DNA, nucleosomes, or chromatin. The results may explain
why some anti-DNA mAbs are very effective at inducing
lupus nephritis, but others are not. Similarly, the results may
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help explain why systemic lupus erythematosus patients with
similar serum anti-dsDNA antibody may have different
susceptibility for lupus nephritis.
RESULTS
In vitro binding of anti-DNA mAb to BM
Culture supernatants from 69 autoimmune anti-DNA mAbs
from eight different (NZB  NZW)F1 mice (BWF1) were
randomly selected for analysis (Table 1). Total IgG and
relative affinity for binding to single-stranded DNA (ssDNA),
dsDNA, chromatin, and BM were quantified for each
supernatant. The mAbs were stratified by relative affinity
for BM into four different specificity groups (Table 1). There
is a significant difference among the four specificity groups
for competitive binding to ssDNA and dsDNA, and direct
binding to BM, but not for direct binding to chromatin.
There is a strong and highly significant correlation between
binding to BM and binding to dsDNA, and a moderate,
highly significant inverse correlation between binding to BM
and binding to ssDNA. Anti-DNA mAbs that bound best to
dsDNA are generally the mAbs that also bound best to BM.
The correlation between BM and chromatin binding,
although significant, was low compared with that for BM
and dsDNA. The results indicate that mAbs with high relative
affinity for dsDNA are more likely to bind BM than mAbs
with high relative affinity for ssDNA. The results also indicate
that anti-DNA mAb binding to BM is unrelated to relative
affinity for chromatin.
The correlations between mAb binding to DNA and
chromatin vs. their potential to bind BM were further
confirmed with purified mAbs (Table 2). BM binding by
purified mAbs was independent of relative binding affinity
Table 1 | Specificity of monoclonal antibodies
Competitive ELISA (ng/ml competitor)b Direct ELISA (ng/ml IgG)c
Groupa Number mAbs ssDNA dsDNA DNA Chromatin BM
A 14 111±84d NI 75±61 826±904 NB
B 21 560±351 5770±2580 6730±6110 1810±2590 NB
C 18 658±302 4200±2580 7040±5560 81±94 5510±1490
D 16 957±469 1570±690 971±1990 52±60 94±780
Abbreviations: BM, basement membrane; dsDNA, double-stranded DNA; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; mAbs, monoclonal antibodies;
NB, no binding with X10,000 ng/ml mAb; NI, no inhibition with 10,000 ng/ml competitor; ssDNA, single-stranded DNA.
aSixty-nine mAbs were stratified according to BM binding into: (A) NB to BM (14 mAb), (B) NB to BM but binding to dsDNA (21 mAb), (C) BM binding withX1000 ng/ml IgG
(18 mAbs), and (D) BM binding with p1000 ng/ml IgG (16 mAbs).
bng/ml competitor is the amount of dsDNA or ssDNA competitor required to produce 50% inhibition of mAb binding to solid phase DNA in a competitive ELISA.24
cng/ml mAb that yields 50% maximum binding in a direct ELISA.
dThe values are means±95% confidence intervals. Analysis of variance among groups for the category of binding to: ssDNA, P=0.025; dsDNA, P=0.033; DNA, P=nonsignificant
(n.s.); chromatin, P=n.s.; BM, P=3.6 108. Linear regression with BM binding as dependent variable (R2=0.465, P=4.3 108): chromatin, B=0.381 and b=0.290, P=0.00298;
ssDNA, B=0.496 and b=0.301, P=0.0022; and dsDNA, B=0.606 and b=0.423, P=0.00010 (B=slope and b=correlation coefficient, PASW Statistics18).
Table 2 |Monoclonal antibody binding to DNA, chromatin, and basement membrane antigens
Direct binding ELISA Competitive ELISA In vivo activity
mAba Isotypeb pIc
DNA
(ng/ml IgG)
Chromatin
(ng/ml IgG)
Nucleosome
(ng/ml IgG)
BM
(g/ml IgG)
ssDNA
(ng/ml ssDNA)
dsDNA
(ng/ml dsDNA)
Glomerular
bindingd
Induces
proteinuriae
163p.64 2a 8.4 60 8.0 19,700 30 470 1030 Yes Yes
163p.77 2b 8.5 20 30 11,500 20 1420 700 Yes Yes
163p.124 2a 8.4 30 4.0 1880 90 1690 470 Yes Yes
DNA6 2a 7.6 10 10 ND 200 2900 1000 Yes Yes
DNA5 2a 8.7 1000 10 ND 3380 1500 10,800 Yes Yes
163p.132 2b 8.5 50 10 50 8600 660 NI Nof Nof
DNA3 2a 6.5 11,000 10 ND NB 54 1600 No No
452s.46 2b 7.6 10 200 2300 NB 730 490 No No
452s.160 2a 7.3 70 90 ND NB 80 4400 No ND
3H9 2b 8.3 4720 50 ND NB ND ND Nog Nog
Abbreviations: BM, basement membrane; dsDNA, double-stranded DNA; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; mAb, monoclonal antibody;
NB, no binding; ND, not done; NI, no inhibition; pI, isoelectric point; ssDNA, single-stranded DNA.
a163p.64, 77, 124 and DNA6: Group D, Table 1; DNA 5 and 163p.132: Group C, Table 1; 452s.46, 160 and DNA3: Group B, Table 1.
bIgG subclass of hybridoma mAb.
cpI of the respective mAb (calculated using the Swiss Institute of Bioinformatics ExPASy pI calculation tool, http://web.expasy.org/compute_pi/).
dGlomerular binding of mAb was determined by immunofluorescence on kidney cryosections 24 h after mice were injected with 1mg purified mAb(s).
eSummary of results presented in Table 3.
fMAb 163p.132, IgG2b produced minimal glomerular fluorescence and no proteinuria 5 days after the injection of hybridoma cells, but readily detected immunofluorescence
and proteinuria 8 days after injection.
gGilkeson et al.31 only 2/5 mice had glomerular-bound IgG, and the glomerular disease score was not different from the negative control.
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for dsDNA, chromatin, or nucleosomes, as 163p.132,
452s.160, DNA3, and 3H9 mAbs bound nucleosomes and/
or chromatin with high relative affinity but bound poorly or
not at all to BM. MAb 452s.46 bound dsDNA with high
relative affinity but did not bind BM. DNA6 mAb bound
chromatin in a manner similar to 163p.132 and DNA3,
but, unlike 163p.132 and DNA3, DNA6 also bound to BM.
MAbs 163p.64, 163p.77, and 163p.124 had 20- to 650-fold
higher relative affinity for BM than for nucleosomes. Binding
to BM was also independent of mAb isoelectric point. These
results further indicate that anti-DNA mAb binding to BM
is correlated with dsDNA binding and to lesser extent
with chromatin binding, but is independent of both for
binding to BM.
As previous investigators had concluded that anti-dsDNA
mAb binding to BM was consequential to nucleosome
contamination of hybridoma supernatants and purified
mAbs,10 we performed co-incubation assays to ensure that
differential binding of anti-dsDNA mAbs to BM was not
simply a consequence of contaminating chromatin in some,
but not all, hybridoma supernatants. When hybridoma
supernatants of mAb pairs 163p.132 and 163p.124, 452s.46
and 163p.64, 163p.77 and DNA3, and 163p.77 and 452s.160
were assayed for binding to BM, only the mAb that bound to
BM in the individual assays, 163p.124, 163p.64, and 163p.77,
bound to BM when co-incubated with a non-BM-binding
mAb (Figure 1 and Table 2). MAb 163p132 does bind BM,
but with 100- to 500-fold less relative affinity than mAbs
163p.64, 77, and 124. The results in Figure 1 corroborate the
conclusion that anti-DNA mAb binding to BM is indepen-
dent of dsDNA or chromatin.
MAb 163p.64 was tested by direct enzyme-linked
immunosorbent assay (ELISA) for binding to individual
components of BM, including laminin, perlecan, entactin,
and agrin. The mAb bound perlecan, entactin, and agrin (59,
250, and 220 ng IgG/ml, respectively, for 50% maximum
binding) but not laminin. The recombinant agrin did not
include the amino-terminal extracellular matrix interaction
domains (R&D Systems). Binding to collagen IV was not
tested. The results indicate that a BM-binding mAb may also
bind to some but not all of the individual components
of GBM.
In vivo glomerular binding of anti-DNA mAbs
Six purified mAbs were further tested for glomerular binding
when injected into non-autoimmune-prone BALB/c mice
alone or co-injected with a mAb with different BM-binding
potential and different IgG subclass. The co-injected pairs
were 163p.77, IgG2b with 452s.160, IgG2a; 163p.64, IgG2a with
452s.46, IgG2b; and 163p.124, IgG2a with 163p.132, IgG2b
(Table 2). The co-injection experiments were included to
exclude the possibility that co-purified chromatin or
nucleosomes influenced glomerular binding.10 Only mAbs
that bound BM by ELISA, 163p77, 16p.64, and 163p.124,
bound glomeruli in vivo when injected either alone or co-
injected with a mAb of different IgG subclass (Table 2 and
Figure 2). Glomerular binding was unrelated to relative
affinity of the mAbs for DNA, chromatin, or mononucleo-
somes, or to IgG subclass.
Confocal microscopy indicated that 163p.64 mAb chroni-
cally injected over a 3-month period was co-localized with
heparan sulfate proteoglycan (HSPG) in GBM and MM, but
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Figure 1 | Supernatant monoclonal antibodies (mAbs) that do not bind basement membrane (BM) when assayed alone do not bind
BM when combined with supernatant mAbs that do bind BM. Supernatant mAbs from the indicated hybridoma pairs were assayed by
direct enzyme-linked immunosorbent assay (ELISA) for BM binding. Titration curves represent serial dilution of supernatants assayed
independently for IgG2a or IgG2b binding to BM: solid circles, IgG2a; open squares, IgG2b; solid lines, IgG2a and IgG2b mAbs co-incubated; and
broken lines, IgG2a or IgG2b mAb incubated alone. Supernatant concentrations of mAbs: 163p.124, 12.1 mg/ml; 163p.132, 34.7 mg/ml; DNA3,
29.1mg/ml; 163p.77, 23.5 mg/ml; 163p.64, 10.0 mg/ml; 452s.46, 6.4mg/ml; and 452s.160, 18.7 mg/ml. Maximum OD405 (optical density at
405 nm)¼ 2.600. IgG, immunoglobulin G; Max, maximum.
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minimally with chromatin (Figure 3a). Glomerular IgG was
also co-localized with HSPG and minimally with chromatin
in autoimmune BWF1 kidneys (Figure 3b). As expected,
there was no glomerular binding of anti-DNA mAb 452s.46
after similar 3-month chronic injection (Figure 3c). Comple-
ment C3 was co-localized with mAb 163p.64 in glomeruli
from chronically injected mice (Figure 3e). These results
indicate that BM-binding anti-DNA antibodies also bind
directly to MM and GBM antigens independently of DNA,
chromatin, or nucleosomes and initiate complement activa-
tion. The small regions of chromatin and IgG co-localization
and perlecan, chromatin, and IgG co-localization in the
kidneys from BALB/c mice chronically injected with 163p.64
mAb (Figure 3a) were more numerous in kidneys from
autoimmune BWF1 (Figure 3b). Those regions of co-
localization may be the glomerular EDS identified by electron
microscopy in the kidneys from autoimmune BWF113 and
anti-DNA mAb–injected mice.11
Only BM-binding anti-DNA mAbs induce proteinuria in
non-autoimmune-prone mice
Ascites tumors were induced in non-autoimmune BALB/c
mice by injecting hybridoma cells either individually or as
co-injected pairs, one producing IgG2a and the other
producing IgG2b (Table 3). Only mice injected with
hybridomas-producing mAbs that bound BM, 163p.64, 77,
or 124 or DNA 5 or 6, had glomerular-bound IgG of the
expected IgG subclass and moderate to severe proteinuria 5
days after hybridoma injection. Mice injected with 163p.64
or 163p.124, IgG2a hybridoma cells with either 452s.46 or
163p.132, IgG2b hybridoma cells had only glomerular-bound
IgG2a. Glomerular IgG binding was not IgG2 subclass
dependent, nor was glomerular binding simply a correlate
of circulating mAb titers. The average serum anti-DNA titer
after 5 days was 25,568 (range 12,000–36,000) for glomerular-
bound mAbs and 31,272 (range 14,000–41,000) for mAbs that
did not bind in glomeruli. Only BM-binding mAbs initiated
glomerular disease detected as proteinuria.
Gilkeson et al.31 observed that mice injected with163p.77
and 163p.132 hybridoma cells developed glomerular IgG
deposits and proteinuria after the injected mice developed
pronounced ascites. The results with 163p.77 are similar to
those in Figure 2 and Table 3. We extended the time before
killing of mice injected with 163p.132 from 5 days to 8 days,
and observed results similar to those of Gilkeson et al. After 8
days, mice injected with 163p.132 cells had glomerular IgG
deposits (Figure 3f) and moderate proteinuria (Table 3). The
difference between 163p.132-injected mice at 5 and 8 days are
likely a consequence of much higher mAb serum titer after 8
days. MAb 163p.132 does bind to BM, but with 300-fold less
relative affinity than mAb 163p.64 (Table 2). Alternatively,
163p.132 mAb deposition after 8 days may have been due to
circulating immune complexes. There was co-localization
of 162p.132 mAb with DNA (yellow pixels in Figure 3f),
although most of the glomerular 163p.132 IgG was not
co-localized with DNA.
DISCUSSION
The present results demonstrate that some but not all anti-
DNA mAbs bind directly to BM antigens and that direct
binding of anti-dsDNA antibody to GBM or MM is critical
for the initiation of experimental lupus nephritis. Glomer-
ular binding of IgG and complement, and the initiation of
glomerular disease, identified as proteinuria, were indepen-
dent of mAb binding to DNA or chromatin whether the
mAbs were injected or produced in situ. MAb binding to
GBM and MM was correlated with relative affinity for
dsDNA, but independent of binding to dsDNA or chromatin.
Only anti-dsDNA mAbs that bound BM antigens bound to
GBM and MM in vivo. These results and conclusion are
consistent with previous reports that anti-dsDNA antibodies
may initiate glomerulonephritis after binding directly to
glomerular antigens.18–24 The results and conclusion contrast
with results10–14,16,17,32 interpreted to indicate that anti-DNA
antibodies can only bind to GBM or MM as immune
complexes of anti-DNA antibody and nucleosomes or by
binding to chromatin already bound to GBM or MM.28–30
The results from co-injection of mice with a hybridoma
producing a BM-binding anti-DNA mAb with a hybridoma
b
a
Figure 2 |Only purified basement membrane (BM)-binding
anti-dsDNA monoclonal antibody (mAb) binds in glomeruli
when injected intravenously into mice. Detection of glomerular
(a) IgG2b, 163p.77 but not (b) IgG2a, 452s.160 in kidney serial
cryosections 24 h after co-injecting 1mg of each purified
monoclonal antibody (mAb) into a BALB/c mouse. Serial
cryosections had granular IgG2b but no IgG2a within mesangial
matrix (MM). Mice injected with 163p.64, IgG2a and 452s.46, IgG2b
(see Figure 3a and c), and 163p.124, IgG2a and 163p.132, IgG2b had
IgG2a but no IgG2b staining. Results were similar in replicate mice.
IgG, immunoglobulin G.
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producing a non-BM-binding anti-DNA mAb are difficult to
reconcile with the previous interpretation. MAbs produced
by the co-injected hybridomas had similar relative affinity for
DNA, nucleosomes, or chromatin, but only the mAbs that
bound BM also bound glomeruli in vivo. The results cannot
be explained by potential absence of circulating nucleosomes
or chromatin in non-autoimmune-prone BALB/c mice.
Circulating or glomerular-bound chromatin or nucleo-
somes, including that released from necrotic or apoptotic
hybridomas, would have been equally accessible to the two
mAbs.
The present results may explain why autoimmune female
BWF1 transgenic for VH of the 3H9 anti-DNA mAb
33,34 do
not develop nephritis.35 3H9 mAb binds DNA and
chromatin36 but does not bind BM. Autoimmune, 3H9 VH
transgenic BWF1 had similar serum IgG2a/b anti-DNA titers
as non-transgenic BWF1 of similar age but did not develop
proteinuria even after 1 year of age. Similar outcome was
reported for D42 VH
37 and 3–32 m38 transgenic BWF1. Non-
transgenic, female BWF1 invariably produce anti-DNA
autoantibody and develop glomerulonephritis with protei-
nuria by 10 months of age.1 BALB/c mice injected with
the 3H9 hybridoma had relatively low glomerular immuno-
fluorescence and disease scores compared with the mice
injected with 163p.77 or 163p.132 hybridomas.31 The
majority of anti-DNA hybridomas from VH3H9 transgenic
BWF1 had VH3H9 H chains.
39 It is likely that those mAbs
could not bind BM and could not initiate disease.
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Figure 3 |Confocal micrographs of kidney cryosections from an autoimmune BWF1 mouse or BALB/c mice injected with
purified anti-DNA monoclonal antibody (mAb). (a, e) One hundred micrograms of 163p.64 mAb administered twice weekly for 3 months;
(b) uninjected BWF1; (c) 100mg 452s.46 mAb administered twice weekly for 3 months; (d) uninjected BALB/c; and (f) BALB/c with 163p.132
hybridoma-induced ascites 8 days after hybridoma injection. Images a and b show chromatin as red, perlecan in glomerular basement
membrane (GBM) and mesangial matrix (MM) as dark blue, and immunoglobulin G (IgG) as green. Co-localization of IgG with heparan
sulfate proteoglycan (HSPG) is clearly identified as turquoise; co-localization of IgG with chromatin, yellow; and co-localization of IgG and
chromatin with HSPG, white. The large white arrowheads in a and b indicate areas of IgG, chromatin, and perlecan co-localization. Small
arrowheads indicate IgG and chromatin co-localization. Image e shows IgG as red and C3 as green with co-localization of 163p.64 mAb and
C3 as yellow. Confocal images a and b: 512 pixels2, 180 nm/pixel (92 mm2), optical sections collected at 0.6-mm intervals; (c–f) 512 pixels2,
450 nm/pixel (230 mm2), optical sections collected at (c–e) 0.8mm intervals and (f) 0.5mm. All images are from optical sections near the center
of respective z-stacks. Replicate mice yielded similar results.
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Essentially three experimental systems have described
nucleosome-dependent glomerular binding of anti-DNA
antibodies. Schmiedeke et al.32 and Termaat et al.17 allowed
soluble DNA to bind to histones after the histones were
perfused into kidneys or added to isolated glomeruli or
GBM. Anti-DNA mAb bound to the immobilized DNA but
not to GBM, histone-coated GBM, or DNA added to GBM.
Although interesting, the experiments do not accurately
reflect the physical and chemical properties of intact
nucleosomes, nor how nucleosomes or chromatin may
interact with GBM or MM. Kramers et al.10 reported that
purified anti-DNA mAbs perfused into kidneys may only
bind in glomeruli as immune complexes with histones or
nucleosomes, presenting as example mAb 32. Nucleosomes in
the immune complexes were presumed to promote binding
to GBM through histone-dependent charge interaction.
Nucleosomes in physiological saline have a net negative
charge with more exposed acidic than basic regions.40,41
The basic termini of H2B and H3 that protrude from
the octamer cores through the DNA superhelix bind with
the acidic patches on the octamer surface of consecutive
nucleosomes and with linker DNA to organize the nucleo-
somes into chromatin.40,42 Nucleosomal organization into
chromatin precludes surface availability of positive charge
contributed by histones.41 The net charge of the GBM lamina
rara interna and externa initially accessible to chromatin or
nucleosomes is anionic43,44 and unlikely to promote binding.
Although nucleosomes bound isolated collagen IV, laminin,15
and agrin16 on laboratory sensor chips, radiolabeled nucleo-
somes45,46 were rapidly cleared from blood into the liver with
insignificant localization to kidneys unless nucleosome
injections were preceded by injection of soluble histones.45
DNA–anti-DNA immune complexes were rapidly cleared
from the circulation in a similar manner.47,48 Perfusion into
the renal artery10 would bypass initial circulation to the liver.
An alternative explanation for why mAb 32–nucleosome
immune complexes bound GBM, but mAb alone did not,
might be that the mAb 32 in nucleosome immune complexes
had increased relative avidity for GBM. The mAb 32–nucleo-
some immune complexes were created at 15:1 molar ratio of
mAb to mononucleosome.10 Multiple unbound antibody
combining sites in mAb 32–nucleosome immune complexes
prepared in antibody excess may have created higher avidity
of the complexes for GBM than mAb 32 alone. The DNA,
nucleosome, and BM-binding characteristics of mAb 32 were
similar to those for mAb 163p.132 in the present study. MAb
163p.132 bound glomeruli only after reaching a serum
concentration of B10 mg/ml. MAbs 163p.64 and 163p.77,
which bind with high relative affinity to BM, both bound
glomeruli at serum concentrations of p720 mg/ml. MAb
163p.132 binds BM, but with low relative affinity. Alter-
natively, the additional 3 days of 163p.132 hybridoma growth
from 5 to 8 days may have produced sufficient chromatin or
nucleosomes from dying cells to produce immune complexes,
likely in mAb excess. There was more glomerular co-
localization of DNA with 163p.132 mAb than with the
BM-binding 163p.64 mAb.
GBM-associated EDS in kidneys from nephritic BWF1,13
nephritic lupus patients,12 and BALB/c mice chronically
injected with an anti-DNA mAb11 contained both chromatin
Table 3 | Hybridomas producing BM-binding mAb induce proteinuria
Hybridoma(s) injecteda mAb isotype Glomerular isotypeb Daysc Anti-DNA serum titer (2a/2b)d Proteinuria (mg/dl)e
163p.64 2a 2a 4 1601/o90 100
2a 5 11 842/o90 300
163p.77 2b 2b 5 o90/36 000 100
163p.124 2a 2a 5 24 000/o90 100
DNA5 2a 2a 5 36 000/o90 100
DNA6 2a 2a 5 36 000/o90 100
452s.46 2b None 5 o90/28 024 o30
DNA3 2a None 5 36 000/o90 o30
163p.132 2b B2bf 5 o90/32 938 o30
2b 8 o90/4200 000 100
163p.64+163p.132 2a+2b 2a 4 2578/4546 100
2a 5 24 704/25 202 300
163p.77+DNA3 2b+2a 2b 5 36 000/36 000 30
163p.124+163p.132 2a+2b 2a 5 24 000/24 000 100
163p.64+452s.46 2a+2b 2a 5 12 001/41 470 100
Abbreviations: BM, basement membrane; mAb, monoclonal antibody.
aTen mice per group were injected with the indicated hybridomas on day 0 and monitored daily for proteinuria. Two mice per group were terminated daily. Results are
presented from one mouse in each group. Similar results were obtained with the other mouse in each group on the respective day.
bThe subclass of IgG detected within serial kidney cryosections was determined by immunofluorescence from kidneys excised on the indicated days after hybridoma
injection.
cThe number of days after injection of hybridoma cells.
dSerum IgG2a and IgG2b anti-DNA titers were determined on the indicated days after hybridoma injection.
eProteinuria measured on the indicated days after hybridoma injection.
fWeak immunofluorescence only slightly above background. Two mice were separately injected with 163p.132 in a later experiment. Sera and kidneys were collected and
proteinuria was measured 8 days after hybridoma injection. See Figure 3f.
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and IgG. The EDS chromatin was presumed to have
originated from mesangial cells undergoing apoptosis.13
The released chromatin was presumed to bind GBM and
present target antigens to chromatin-binding antibody.
Caspase 3–positive mesangial cells were detected in kidneys
from nephritic but not pre-nephritic BWF1,13 and chromatin
was never detected in EDS that did not contain IgG as
well.11,13 Direct binding of nucleosomes or chromatin to
GBM was not tested. If chromatin binding to GBM
determines when and where anti-DNA antibody binds
GBM to initiate EDS, mAbs with similar relative affinity
for chromatin should have similar potential to initiate
nephritis, which our results show not to be true. Nucleo-
somes do not bind GBM as discussed above. The recent
morphological studies have elegantly refined our under-
standing of glomerular EDS in nephritic kidneys12–14,16,49 but
fail to clarify how EDS are initiated in lupus nephritis.
Earlier experiments determined that small lattice immune
complexes prepared with a cationized antibody were retained
within glomerular subendothelial EDS but persisted only
when they were able to form larger lattice immune
complexes.50 Glomerular mAb deposition in the present
study was independent of mAb isoelectric point or immune
complexes. Immune complex deposition in GBM can also be
initiated by GBM-binding antibody that also binds circulating
free antigen to produce immune complexes and EDS.51 Our
results are most consistent with this latter mechanism to
explain how anti-DNA antibody can initiate glomerular EDS
(illustrated in Figure 4). The initial event toward glomerular
IgG binding and initiation of EDS is direct binding of anti-
DNA antibody to GBM or MM (Figure 4 I). Complement
activation and the ensuing inflammation could provide a
source for locally released oligonucleosomes. If the locally
released oligonucleosomes are bound by GBM or MM-bound
antibody (Figure 4 II),51 both BM-binding and non-BM-
binding anti-DNA antibodies could bind the progressively
accumulating complex and induce more complement activa-
tion, inflammation, and oligonucleosome release (Figure 4
III). Reduced glomerular DNase I would contribute to and
accelerate stage III (Figure 4).52 The progressive accumulation
of immune complexes would eventually produce chronic
inflammation and lupus nephritis. BM-binding and non-BM-
binding anti-DNA mAbs were not co-localized in mice 5 days
after co-injection with respective hybridomas. There may have
been insufficient circulating oligonucleosomes or chromatin
from the ascites tumors to generate the glomerular complexes
depicted in Figure 4 II. Similarly, 3H9 transgenic BWF1 may
fail to develop glomerulonephritis not only because the
transgenic anti-DNA antibody cannot bind glomerular
antigens, but also because locally released oligonucleosomes
are unavailable to create large lattice immune complexes.
Anti-DNA antibodies that bind directly to glomerular
endothelial, mesangial, or other cell surface antigens can
function in a manner similar to anti-DNA antibodies that
bind GBM or MM.19–21,23,53–55 Cell-bound anti-DNA anti-
bodies can initiate inflammation by directly altering cell
function, inducing apoptosis or necrosis, or interrupting
cell–cell or cell–matrix interactions.6,56 Oligonucleosomes
released from apoptotic or necrotic cells as a consequence
of the induced inflammation can form large lattice immune
complexes locally,50 which persist as subendothelial EDS.13
Our results do not exclude the potential for GBM binding
of circulating nucleosome–antibody immune complexes10 or
antibody binding to GBM chromatin, but they do indicate
that neither is necessary for BM-binding anti-DNA antibody
to bind GBM or MM.21,23,52
We did not directly test whether injected anti-DNA mAbs
would bind differently in nephritic or pre-nephritic BWF1
kidneys compared with BALB/c mouse kidneys. Confocal
images of IgG co-localization with GBM and MM in the
kidneys from 9-month-old BWF1 were similar to those from
BALB/c mice chronically injected with BM-binding anti-
DNA mAb.
The present results provide additional insight to explain
why lupus patients with similar serum antibody to dsDNA or
nucleosomes can have different antibody-dependent disease
outcomes.6
MATERIALS AND METHODS
Mice
BALB/c mice were purchased from Harlan Sprague-Dawley
(Indianapolis, IN) and maintained within the UTHSC Laboratory
Animal Care Unit. All experimental protocols were approved by
IACUC.
Antibodies and antigens
The generation, DNA specificity, and V-region sequences for the
mAbs used in these studies have been described.34,57–59 All
hybridomas were derived from autoimmune (NZB  NZW)F1
mice (BWF1), except for 3H9,34 which was provided by Drs M
Weigert and M Radic (Chicago, IL and Memphis, TN). Matrigel
(BM; BD Biosciences, Bedford, MA) is a soluble basement
membrane matrix of laminin, collagen IV, HSPG, and entactin
(nidogen 1). Only high-molecular-weight bands corresponding
to laminin, collagen IV, entactin, and HSPG were detected after
high-sensitivity staining of an SDS-PAGE of 12.5 mg of Matrigel.
*
I
II
III
*
*
*
Figure 4 |Hypothetical mechanism for the initiation of lupus
nephritis by basement membrane (BM)–binding anti-double-
stranded DNA (dsDNA) antibody. The stage I to II transition is
likely to be reversible.62 The stage II to III transition associated
with the progressive accumulation of antibody and chromatin
into immune complexes will eventually reach a threshold for
which the immune complex deposition is no longer reversible.
This stage would yield chronic inflammation and lupus nephritis.
Electron-dense substance (EDS)11,12,27 is predicted to be formed
by the stage II to III transition. , GBM or MM; , chromatin;
, BM-binding anti-dsDNA; , non BM-binding anti-dsDNA;
*, activated complement.
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DNA, ssDNA, and dsDNA were prepared as described.58 Chromatin
and mononucleosomes were isolated from mouse liver or from
cultured P3x63-Ag8.653 cells as described.60 Perlecan (HSPG2) and
heparan sulfate were purchased from Sigma-Aldrich (St Louis, MO),
and recombinant human nidogen (entactin) and C-terminal
recombinant rat agrin from R&D Systems (Minneapolis, MN).
Agrin is a heparan sulfate proteoglycan in GBM.61 Biotinylated goat
anti-mouse IgG, IgG2a, and IgG2b, fluorescein isothiocyanate
(FITC)-goat anti-mouse IgG, and FITC-streptavidin were purchased
from Southern Biotechnology (Birmingham, AL); alkaline phos-
phatase-streptavidin from Jackson Immunoresearch Laboratories
(West Grove, PA); biotinylated rat anti-perlecan mAb (clone A7L6)
from Lab Vision (Thermo Fisher Scientific, Fremont, CA); Alexa
546-strepatavidin and TO-PRO3 DNA dye from Molecular Probes
(Invitrogen, Carlsbad, CA); and anti-C3-FITC from BD Bioscience.
MAb isolation
MAbs were isolated from hybridoma supernatants by affinity
chromatography on protein G-Sepharose 4B (Invitrogen) essentially
as described.10 MAbs were eluted with glycine–HCl, pH 2.8, and
immediately neutralized. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis of eluted mAbs stained with a high-sensitivity
Coomassie (Biorad, Hercules, CA) yielded bands corresponding
only to immunoglobulin H and L polypeptides. DNA was not
detected in purified mAbs by ethidium bromide staining after
agarose electrophoresis, but was detected in the high-salt eluate.
ELISA for DNA, chromatin, nucleosome, and BM binding
Direct and competitive ELISAs for DNA binding were performed as
described.59 ELISAs for mAb binding to chromatin, nucleosomes,
BM, and the BM constituents HSPG, heparan sulfate, and entactin
were performed identically to the direct DNA ELISA. Plates
(Immulon I, Thermo-Fisher) were coated with DNA, chromatin,
or mononucleosomes at 1 mg/well DNA; 1/250 dilution of Matrigel,
B5 mg/well, estimated as 2.8 mg/well laminin, 1.5 mg/well collagen IV,
0.4mg/well entactin, and 0.25 mg/well HSPG (BD Bioscience assay);
or 0.2 mg/well of purified BM proteins. Bound IgG from serially
diluted supernatant, purified mAb, or serum antibody were detected
as described.59 A biotinylated rat anti-laminin mAb (clone A5;
Neomarkers, Thermo Fisher Scientific, Kalamazoo, MI) was used as a
positive control for the anti-BM ELISA. Statistical analyses were per-
formed with PASW Statistics 18 (SPSS Statistics, IBM, Armonk, NY).
In vivo glomerular binding of anti-DNA mAb and
measurement of proteinuria
BALB/c mice, 8–12 weeks old, were injected once intravenously with
1 mg of a single, purified mAb or 1 mg each of two purified mAbs,
one IgG2a, the other IgG2b. After 24 h, injected mice were killed and
their kidneys were removed and snap-frozen in optimum cutting
temperature embedding medium (Tissue-Tek, Miles Laboratories,
Elkhart, IN). Serial 1-mm cryosections were fluorescently stained
with biotinylated goat anti-mouse IgG2a or IgG2b and FITC-
streptavidin. In separate experiments, mice were chronically injected
with 100mg per intraperitoneal injection of a single mAb twice
weekly for 3 months or injected intraperitoneal with hybridoma cells
5–7 days after intraperitoneal injection with 0.5 ml pristane (Sigma).
The hybridoma injection consisted of 107 cells from one hybridoma
or 107 cells each from two hybridomas, one producing IgG2a and the
other producing IgG2b. Kidneys were removed and embedded for
cryosection after 3 months chronic injection of purified mAb or
1–5 days after hybridoma injection. Serial cryosections from the
same kidney were stained for detection of mouse IgG2a or IgG2b. For
confocal microscopy, 4–12 mm cryosections were stained with TO-
PRO3 for DNA, goat anti-mouse IgG-FITC, and rat anti-perlecan
and streptavidin Alexa 546, or anti-C3-FITC and biotinylated goat
anti-mouse IgG and streptavidin-Alexa 546. Confocal images were
collected with a Zeiss LSM510 confocal microscope (Carl Zeiss
Microimaging, Thornwood, NY). Proteinuria was measured with
Ames Uristix (Miles) according to the manufacturer’s instructions.
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